Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation

NCT03217734 is registered in ClinicalTrials.gov with Jeffrey J Crowley MD as lead sponsor.

NCT NCT03217734
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03217734 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MAP Study (Methotrexate and Adalimumab in Psoriasis): Adalimumab vs. Combination Adalimumab and Methotrexate in Psoriasis: Efficacy and Anti-Adalimumab Antibody Formation
Lead sponsor
Jeffrey J Crowley MD
Phase
Phase 2/3
Overall status
Completed
Start date
April 10, 2017
Completion date
December 31, 2018
Enrollment
56 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis